 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
Trial completion: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty (clinicaltrials.gov) - Oct 30, 2023
P2, N=40, Completed, Sponsor: MyMD Pharmaceuticals, Inc.
Recruiting --> Completed
- | isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
Trial completion date, Trial primary completion date: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty (clinicaltrials.gov) - Mar 14, 2023
P2, N=40, Recruiting, Sponsor: MyMD Pharmaceuticals, Inc.
Recruiting --> Completed Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Nov 2022 --> Jul 2023
- | metformin / Generic mfg., sirolimus / Generic mfg., isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
Preclinical, Journal, Head-to-Head: MyMD-1 improves health span and prolongs lifespan in old mice: A non-inferiority study to rapamycin. (Pubmed Central) - Mar 2, 2023
Many were shared with rapamycin, but MyMD-1 was more active in the inhibition of pro-inflammatory and pro-fibrotic biomarkers. Overall, MyMD-1 emerges as a new compound that, even when begun at an advanced age, induces beneficial effects on health and lifespan by modulating inflammation and tissue remodeling.
- || isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
P1 data, PK/PD data, Journal: A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects. (Pubmed Central) - Nov 15, 2022
Overall, MyMD-1 emerges as a new compound that, even when begun at an advanced age, induces beneficial effects on health and lifespan by modulating inflammation and tissue remodeling. Isomyosamine will continue to be investigated in phase 2 clinical trials for the treatment of sarcopenia/frailty, hashimoto's thyroiditis and rheumatoid arthritis.
- ||| isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
$MYMD MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions https://t.co/3tegNspjPj (Twitter) - Jul 12, 2022
- | isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
Trial completion date, Trial primary completion date: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty (clinicaltrials.gov) - Apr 1, 2022
P2, N=40, Recruiting, Sponsor: MyMD Pharmaceuticals, Inc.
Isomyosamine will continue to be investigated in phase 2 clinical trials for the treatment of sarcopenia/frailty, hashimoto's thyroiditis and rheumatoid arthritis. Trial completion date: Jun 2023 --> Dec 2022 | Trial primary completion date: May 2023 --> Nov 2022
- || isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
New P2 trial: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty (clinicaltrials.gov) - Mar 16, 2022
P2, N=40, Recruiting, Sponsor: MyMD Pharmaceuticals, Inc.
- |||| isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
New P2 trial: Assessing the Safety and Efficacy of MYMD1 to Treat Depression in Patients With Post-Acute Sequelae of Coronavirus Disease-2019 (PASC) (clinicaltrials.gov) - Feb 16, 2022
P2, N=90, Not yet recruiting, Sponsor: Johns Hopkins University
- || isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
New P1 trial: Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects (clinicaltrials.gov) - Oct 14, 2021
P1, N=32, Completed, Sponsor: MyMD Pharmaceuticals, Inc.
- | isomyosamine (MYMD1) / MyMD Pharma
Journal: MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis. (Pubmed Central) - Jul 10, 2020
MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.
- | isomyosamine (MYMD-1) / MyMD Pharma, Akers Biosci
New P1 trial: Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects (clinicaltrials.gov) - Apr 15, 2020
P1, N=40, Completed, Sponsor: MyMD Pharmaceuticals, Inc.